What is OpenBiome?
OpenBiome operates as a specialized non-profit organization at the intersection of clinical medicine and microbiome research. The company is primarily recognized for its efforts to expand patient access to fecal microbiota transplantation (FMT) therapies, specifically targeting the treatment of Clostridioides difficile (C. diff) infections. By providing a standardized, safe, and accessible supply of investigational therapies, OpenBiome serves as a vital infrastructure provider for healthcare systems and research institutions globally. Their model emphasizes open-access resources, which facilitates collaborative scientific discovery and accelerates the development of next-generation microbiome-based treatments. Through these initiatives, the organization effectively manages the complexities of clinical supply chains while maintaining a rigorous focus on safety and efficacy standards.
How much funding has OpenBiome raised?
OpenBiome has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in OpenBiome
PPP
Public-Private Partnership
What's next for OpenBiome?
With the recent influx of capital, OpenBiome is well-positioned to transition into a more robust phase of enterprise-level growth. The organization is expected to prioritize the expansion of its research pipeline and the enhancement of its clinical distribution networks. Strategic focus will likely shift toward scaling the production of investigational therapies and deepening partnerships with academic and commercial entities to explore broader applications of the human microbiome. As the regulatory landscape for microbiome-based interventions evolves, OpenBiome's ability to maintain its role as a reliable, high-quality supplier will be essential for sustaining its long-term impact on public health outcomes and therapeutic innovation.
See full OpenBiome company page
